Related Experiment Video
Updated: May 25, 2026

Dissection of Drosophila Ovaries
Published on: October 19, 2006
Foxo3a transcription factor is a negative regulator of Skp2 and Skp2 SCF complex
1State Key Laboratory of Oncology in South China and Department of Experimental Research, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Abstract:
Skp2 (S-phase kinase-associated protein-2) SCF complex displays E3 ligase activity and oncogenic activity by regulating protein ubiquitination and degradation, in turn regulating cell cycle entry, senescence and tumorigenesis. The maintenance of the integrity of Skp2 SCF complex is critical for its E3 ligase activity. The Skp2 F-box protein is a rate-limiting step and key factor in this complex, which binds to its protein substrates and triggers ubiquitination and degradation of its substrates. Skp2 is found to be overexpressed in numerous human cancers, which has an important role in tumorigenesis. The molecular mechanism by which the function of Skp2 and Skp2 SCF complex is regulated remains largely unknown. Here we show that Foxo3a transcription factor is a novel and negative regulator of Skp2 SCF complex. Foxo3a is found to be a transcriptional repressor of Skp2 gene expression by directly binding to the Skp2 promoter, thereby inhibiting Skp2 protein expression. Surprisingly, we found for the first time that Foxo3a also displays a transcription-independent activity by directly interacting with Skp2 and disrupting Skp2 SCF complex formation, in turn inhibiting Skp2 SCF E3 ligase activity and promoting p27 stability. Finally, we show that the oncogenic activity of Skp2 is repressed by Foxo3a overexpression. Our results not only reveal novel insights into how Skp2 SCF complex is regulated, but also establish a new role for Foxo3a in tumor suppression through a transcription-dependent and independent manner.
Insights
Foxo3a suppresses cancer by inhibiting Skp2 SCF complex formation and activity. This transcription factor acts both by reducing Skp2 gene expression and by directly disrupting the Skp2 complex, repressing oncogenic activity.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Biology
Background:
- Skp2 (S-phase kinase-associated protein-2) SCF complex is an E3 ligase crucial for cell cycle regulation and tumorigenesis.
- Skp2 overexpression is common in human cancers, highlighting its oncogenic role.
- Mechanisms regulating Skp2 SCF complex activity remain incompletely understood.
Purpose of the Study:
- To identify novel regulators of the Skp2 SCF complex.
- To elucidate the role of Foxo3a in regulating Skp2 SCF complex activity and function.
- To investigate the tumor suppressive mechanisms of Foxo3a in relation to Skp2.
Main Methods:
- Analysis of Skp2 gene expression regulation by Foxo3a.
- Investigation of Foxo3a's direct interaction with Skp2.
- Assessment of Skp2 SCF complex integrity and E3 ligase activity upon Foxo3a modulation.
- Evaluation of p27 stability and oncogenic Skp2 activity in the presence of Foxo3a.
Main Results:
- Foxo3a acts as a transcriptional repressor of Skp2 gene expression by binding to the Skp2 promoter.
- Foxo3a directly interacts with Skp2, disrupting Skp2 SCF complex formation and inhibiting its E3 ligase activity.
- Foxo3a promotes p27 stability and represses the oncogenic activity of Skp2.
- Foxo3a demonstrates tumor suppressive functions through both transcription-dependent and independent mechanisms.
Conclusions:
- Foxo3a is a novel negative regulator of the Skp2 SCF complex.
- Foxo3a suppresses tumorigenesis via dual mechanisms: transcriptional repression of Skp2 and direct disruption of the Skp2 complex.
- These findings establish a new role for Foxo3a in tumor suppression and provide insights into Skp2 SCF complex regulation.
Related Concept Videos
Master Transcription Regulators
Master Transcription Regulators
Co-activators and Co-repressors
Co-activators and Co-repressors
Negative Regulator Molecules
Regulation of Expression at Multiple Steps

